Promedior is a clinical stage biopharmaceutical company developing novel therapeutics for the treatment of fibrosis.

Fibrosis is one of the greatest unmet needs in medicine today. Promedior is pioneering the development of targeted therapeutics to treat fibrotic diseases by regulating the innate immune system response to injury.

Utilizing an entirely new approach, Promedior has developed a proprietary platform of pentraxin therapeutics based upon breakthrough discoveries in how monocyte-derived cells – such as macrophages, fibrocytes and dendritic cells – control the initiation, progression and resolution of fibrosis.

Promedior’s pentraxin therapeutics promote healing of damaged tissue by naturally targeting monocyte-derived cells at the site of injury and directing their differentiation into pro-resolution regulatory macrophages.